Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.

Pembrolizumab will be administered at 200mg IV on day 1 of each 21 day cycle.

Guadecitabine will be administered subcutaneously given daily on days 1-5 of each cycle with escalating doses by cohort.

Mocetinostat will be administered orally with escalating doses on days 8, 10, 13, 15, 17 and 20 of each cycle with escalating doses by cohort.